CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionReturn on equity is 22.7%, higher than 95% of its Medical Devices peers (median 3%)
- FinancialsAltman Z-Score 7.16: safe zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.02%
Annual Rate
KRW 50.00Paid annual
Payout Ratio
13.3%Sustainable
Payback Period
92.3 yr
Last Ex-Dividend
Dec 29, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
433.45BKRW312.33M · vs all stocks (USD)
Trailing P/E
12.43xvs Medical Devices peers
Revenue (TTM)
159.67BKRW115.05M · vs all stocks (USD)
Profit Margin
21.12%vs Medical Devices peers
Beta
0.9320xvs all stocks
52-Week Change
-51.34%vs all stocks
Market Capitalization
433.45BKRW312.33M · vs all stocks (USD)
Enterprise Value
395.35BKRW284.87M · vs all stocks (USD)
Trailing P/E
12.43xvs Medical Devices peers
Forward P/E
7.02xvs Medical Devices peers
PEG Ratio
-1.03xvs Medical Devices peers
Price to Sales (TTM)
2.86xvs Medical Devices peers
Price to Book (MRQ)
2.67xvs Medical Devices peers
Enterprise to Revenue
2.48xvs Medical Devices peers
Enterprise to EBITDA
7.69xvs Medical Devices peers
Gross Margin
71.09%vs Medical Devices peers
Profit Margin
21.12%vs Medical Devices peers
Operating Margin
27.83%vs Medical Devices peers
Return on Assets (TTM)
14.46%vs Medical Devices peers
Return on Equity (TTM)
22.66%vs Medical Devices peers
Revenue (TTM)
159.67BKRW115.05M · vs all stocks (USD)
Revenue per Share (TTM)
1.78KKRWUpdated Aug 20, 2026Quarterly Revenue Growth
7.60%vs Medical Devices peers
Gross Profit (TTM)
110.15BKRW79.37M · vs all stocks (USD)
EBITDA (TTM)
51.34BKRW36.99M · vs all stocks (USD)
Net Income (TTM)
33.72BKRW24.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.60%vs Medical Devices peers
Operating Cash Flow (TTM)
30.35BKRW21.87M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
20.63BKRW14.86M · vs all stocks (USD)
Trailing Annual Dividend Rate
50.00KRWUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.02%vs all stocks
Payout Ratio
13.33%vs Medical Devices peers
Revenue
156.84BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
51.04BKRWFY2025 · Dec 31, 2025Gross Profit
105.79BKRWFY2025 · Dec 31, 2025Operating Income
51.69BKRW37.24M · vs all stocks (USD)
Pre-tax Income
46.16BKRWFY2025 · Dec 31, 2025Income Tax Expense
10.94BKRWFY2025 · Dec 31, 2025Net Income
35.22BKRWFY2025 · Dec 31, 2025EBIT
48.56BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
53.18BKRWFY2025 · Dec 31, 2025Research & Development
1.89BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
33.54BKRWFY2025 · Dec 31, 2025Other Operating Expenses
1.69BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
2.35BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.40BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
35.22BKRWFY2025 · Dec 31, 2025Operating Cash Flow
38.03BKRWFY2025 · Dec 31, 2025Free Cash Flow
36.84BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
32.50BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
35.22BKRWFY2025 · Dec 31, 2025Other Non-cash Items
701.36MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-4.13BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.24BKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.19BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-127.57MKRWFY2025 · Dec 31, 2025Net Acquisitions
-18.59BKRWFY2025 · Dec 31, 2025Purchase of Investments
-239.44BKRWFY2025 · Dec 31, 2025Sale of Investments
220.00BKRWFY2025 · Dec 31, 2025Other Investing Activity
-10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-39.22BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-4.49MKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-4.49MKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-6.00BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-4.45BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-10.24BKRWFY2025 · Dec 31, 2025Shares Outstanding
89.22MSharesUpdated Aug 20, 2026Float Shares
41.96MSharesUpdated Aug 20, 2026% Held by Insiders
52.36%vs all stocks
% Held by Institutions
2.80%vs all stocks
Total Cash (MRQ)
99.35BKRW71.59M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.11KKRWUpdated Aug 20, 2026Total Debt (MRQ)
20.92BKRW15.08M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1280xvs Medical Devices peers
Current Ratio (MRQ)
3.05xvs Medical Devices peers
Book Value per Share (MRQ)
1.83KKRWUpdated Aug 20, 2026Total Assets
217.25BKRW156.54M · vs all stocks (USD)
Total Current Assets
183.57BKRWFY2025 · Dec 31, 2025Total Liabilities
59.87BKRWFY2025 · Dec 31, 2025Total Non-current Assets
33.67BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
487.29MKRWFY2025 · Dec 31, 2025Total Current Liabilities
59.38BKRWFY2025 · Dec 31, 2025Cash
32.50BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
32.50BKRWFY2025 · Dec 31, 2025Other Short-term Investments
75.23BKRWFY2025 · Dec 31, 2025Accounts Receivable
20.58BKRWFY2025 · Dec 31, 2025Inventory
47.36BKRWFY2025 · Dec 31, 2025Accounts Payable
2.86BKRWFY2025 · Dec 31, 2025Short-term Debt
18.87BKRWFY2025 · Dec 31, 2025Other Current Liabilities
6.81BKRWFY2025 · Dec 31, 2025Long-term Debt
487.29MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
10.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
9.00BKRWFY2025 · Dec 31, 2025Retained Earnings
104.83BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
157.38BKRW113.40M · vs all stocks (USD)
Treasury Stock
6.00BKRWFY2025 · Dec 31, 202552-Week Low
4.13KKRWUpdated Aug 20, 202652-Week High
11.43KKRWUpdated Aug 20, 202652-Week Change
-51.34%vs all stocks
Beta
0.9320xvs all stocks
50-Day MA
5.72KKRWUpdated Aug 20, 2026200-Day MA
7.27KKRWUpdated Aug 20, 2026Avg 10-Day Volume
610.44KSharesUpdated Aug 20, 2026Avg 30-Day Volume
617.19KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
393.00KRWUpdated Aug 20, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 22.7%, higher than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: 0.23Industry median: 0.03Industry P95: 0.17Peers compared: 102
Return on assets is 14.5%, higher than 95% of its Medical Devices peers (median 1.9%)Significant
Return on assets: 0.14Industry median: 0.02Industry P95: 0.12Peers compared: 102
P/E ratio is 12.43×, lower than 95% of its Medical Devices peers (median 31.47×)Notable
P/E ratio: 12.43Industry median: 31.47Industry P5: 13.95Peers compared: 102
Financial Health
Altman Z-Score 7.16: safe zoneNotable
Altman Z-Score: 7.16
High structural barrier to entryNotable
Barrier to Entry: 0.63
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Donghua Testing Technology Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
JYP Entertainment Corporation
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Transaction Co Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity